Hepatitis C virus antigen-specific T cells (HCV-specific T cells)

Hepatitis C virus (HCV) antigen-specific T cells are a specialized population of the adaptive immune system, comprising both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells that recognize viral epitopes presented by major histocompatibility complex (MHC) molecules. In acute HCV infection, a robust and multi-specific T-cell response is associated with viral clearance; however, in chronic infection, these cells often undergo 'exhaustion,' characterized by the loss of effector functions and the high expression of inhibitory receptors like PD-1. As a therapeutic target, these cells are the focus of immunotherapies aimed at restoring their antiviral activity, such as checkpoint inhibitors or therapeutic vaccines designed to broaden the T-cell repertoire. Understanding the phenotypic and functional state of these cells is critical for developing strategies to achieve a functional cure for chronic hepatitis C and preventing the progression to cirrhosis or hepatocellular carcinoma.

Other names

HCV-specific T lymphocytesHepatitis C virus-specific T-cell responseHCV-reactive T cellsHCV-specific CD8+ T cellsHCV-specific CD4+ T cells

Modulation of T-cell activity through checkpoint inhibition (e.g., PD-1 blockade) to reverse exhaustion, or induction of T-cell expansion and activation via therapeutic vaccination or adoptive cell transfer.